Industry
Featured experience
Novo Nordisk acquisition of certain Catalent sites from Novo Holdings
We are advising Novo Nordisk on the acquisition
AbbVie $15 billion senior notes offering
The investment-grade offering comprised seven tranches
Auna $360 million U.S. IPO
We advised Auna on its U.S. IPO and NYSE listing
Trial victory in patent infringement case for Magnolia Medical Technologies
We served as lead trial counsel for Magnolia Medical in an action against its sole competitor
Esperion Therapeutics $250 million convertible senior subordinated notes
Davis Polk advised the representatives of the initial purchasers in connection with a Rule 144A offering by Esperion…
Maravai LifeSciences Holdings $1.863 billion IPO
Davis Polk advised the representatives of the several underwriters in connection with the initial public offering of 69…
Stoke Therapeutics $112 million follow-on offering
Davis Polk advised the representatives of the underwriters in connection with the $112 million public offering of 2,500,000…
Berkeley Lights $258 million secondary offering
Davis Polk advised the representatives of the several underwriters in connection with the $258 million SEC-registered…
Olema Pharmaceuticals $240 million IPO
Davis Polk advised the representatives of the several underwriters in connection with the $240 million initial public…
Signify Health acquisition of PatientBlox
Davis Polk advised Signify Health on its acquisition of PatientBlox. The acquisition accelerates Signify’s prospective…
Antengene HK$2.79 billion IPO
Davis Polk advised Antengene Corporation Limited in connection with its initial public offering and listing on the Hong Kong…
Auna $300 million high-yield notes offering
Davis Polk advised Auna S.A.A. in connection with its Rule 144A/Regulation S offering of $300 million aggregate principal…
Kodiak Sciences $645 million follow-on offering
Davis Polk advised the joint book-running managers and representatives of the several underwriters in connection with a $645…
China Biologic going-private transaction
Davis Polk is advising the special committee of the board of directors of China Biologic Products Holdings, Inc. (“China…